The July 2026 meeting of the PBAC includes six submissions from companies seeking variations to previously considered or recommended listings, suggesting an increasingly challenging access environment for pharmaceutical companies.
PBAC agenda reflects increasing number of companies seeking revised recommendations
March 25, 2026 Latest NewsBioPharmaNews of the Day
Latest Video
New Stories
-
ARCS launches national partnership to boost public clinical research sites
May 27, 2026 - - Latest News -
Australia’s access dilemma and how commercial leaders have adapted over time
May 27, 2026 - - Latest News -
TGA approves Sanofi innovation that offers the chance to delay onset of type 1 diabetes
May 27, 2026 - - Latest News -
This unique historical oddity says all we need to know about the institution
May 26, 2026 - - Latest News -
New Zealand's Pharmac consulting on new vaccine brands and wider flu access for young children
May 26, 2026 - - Latest News -
New national survey reveals muscle health screening gap in Australian general practice
May 26, 2026 - - Latest News -
Mayne Pharma awarded legal costs as business expansion gains momentum
May 25, 2026 - - Latest News
